Neuropathology of Autosomal Dominant Alzheimer Disease in the National Alzheimer Coordinating Center Database
- PMID: 26888304
- PMCID: PMC4934612
- DOI: 10.1093/jnen/nlv028
Neuropathology of Autosomal Dominant Alzheimer Disease in the National Alzheimer Coordinating Center Database
Abstract
Alzheimer disease (AD) represents a genetically heterogeneous entity. To elucidate neuropathologic features of autosomal dominant AD ([ADAD] due to PSEN1, APP, or PSEN2 mutations), we compared hallmark AD pathologic findings in 60 cases of ADAD and 120 cases of sporadic AD matched for sex, race, ethnicity, and disease duration. Greater degrees of neuritic plaque and neurofibrillary tangle formation and cerebral amyloid angiopathy (CAA) were found in ADAD (p values < 0.01). Moderate to severe CAA was more prevalent in ADAD (63.3% vs. 39.2%, p = 0.003), and persons with PSEN1 mutations beyond codon 200 had higher average Braak scores and severity and prevalence of CAA than those with mutations before codon 200. Lewy body pathology was less extensive in ADAD but was present in 27.1% of cases. We also describe a novel pathogenic PSEN1 mutation (P267A). The finding of more severe neurofibrillary pathology and CAA in ADAD, particularly in carriers of PSEN1 mutations beyond codon 200, warrants consideration when designing trials to treat or prevent ADAD. The finding of Lewy body pathology in a substantial minority of ADAD cases supports the assertion that development of Lewy bodies may be in part driven by abnormal β-amyloid protein precursor processing.
Keywords: Alzheimer disease; Amyloid plaques; Autosomal dominant; Cerebral amyloid angiopathy; Neurofibrillary tangles; Neuropathology; P267A..
© 2016 American Association of Neuropathologists, Inc. All rights reserved.
References
-
- Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer’s disease: Progress and problems on the road to therapeutics. Science 2002;297:353–6 - PubMed
-
- Scheuner D, Eckman C, Jensen M, et al. Secreted amyloid β-protein similar to that in the senile plaques of Alzheimer’s disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer’s disease. Nat Med 1996;2:864–70 - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- UL1 RR033176/RR/NCRR NIH HHS/United States
- P50 AG016574/AG/NIA NIH HHS/United States
- P50 AG023501/AG/NIA NIH HHS/United States
- U01 AG051218/AG/NIA NIH HHS/United States
- P50 AG-005142/AG/NIA NIH HHS/United States
- P50 AG005142/AG/NIA NIH HHS/United States
- P50 AG016573/AG/NIA NIH HHS/United States
- 1UL1-RR033176/RR/NCRR NIH HHS/United States
- P30 AG010124/AG/NIA NIH HHS/United States
- P30 AG010133/AG/NIA NIH HHS/United States
- M01 RR000865/RR/NCRR NIH HHS/United States
- U01 AG016976/AG/NIA NIH HHS/United States
- P50 AG005681/AG/NIA NIH HHS/United States
- P50 AG005136/AG/NIA NIH HHS/United States
- P30 AG012300/AG/NIA NIH HHS/United States
- P30 AG008051/AG/NIA NIH HHS/United States
- UL1 TR001422/TR/NCATS NIH HHS/United States
- P50AG005146/AG/NIA NIH HHS/United States
- P50 AG016570/AG/NIA NIH HHS/United States
- P50 AG025688/AG/NIA NIH HHS/United States
- P50 AG005133/AG/NIA NIH HHS/United States
- P30 AG028383/AG/NIA NIH HHS/United States
- P50 AG008702/AG/NIA NIH HHS/United States
- P30 AG010161/AG/NIA NIH HHS/United States
- P50 AG005138/AG/NIA NIH HHS/United States
- P50 AG005131/AG/NIA NIH HHS/United States
- P30 AG010129/AG/NIA NIH HHS/United States
- P30 AG019610/AG/NIA NIH HHS/United States
- P30 AG008017/AG/NIA NIH HHS/United States
- P30 AG013854/AG/NIA NIH HHS/United States
- P30 AG013846/AG/NIA NIH HHS/United States
- P30 AG035982/AG/NIA NIH HHS/United States
- P50 AG005134/AG/NIA NIH HHS/United States
- P50 AG033514/AG/NIA NIH HHS/United States
- U19 AG032438/AG/NIA NIH HHS/United States
- P50 AG-16570/AG/NIA NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical